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Abstract: Dapper, Dishevelled-associated antagonist of β-catenin (DACT), is a key regulator of Wnt signaling path-
way. The purpose of this study is to explore the epigenetic changes and the function ofDACT2 in human gastric 
cancer (GC). Eight human gastric cancer cell lines, 167 cases of primary gastric cancer and 8 cases of normal 
gastric mucosa were involved in this study. In addition, methylation Specific PCR (MSP), semi-quantitative RT-PCR, 
colony formation assay, flow cytometry assay, siRNA, immunofluorescence techniques and xenograft mice models 
were employed. The results indicate that DACT2 is frequently methylated in human primary gastric cancer (55.7%), 
and that methylation of DACT2 is associated with lost or reduction in its expression (X2 test, P<0.01). We found 
that DACT2 expression was regulated by promoter region hypermethylation. Methylation of DACT2 is associated 
with tumor differentiation, invasion and intravascular cancerous emboli (X2 test, P<0.05, P<0.05 and P<0.05). In 
gastric cancer patients treated with 5-FU and cisplatin, the five-year survival rates are higher in DACT2 methylated 
cases. DACT2 inhibits cell proliferation, migration and invasion in gastric cancer cells and suppresses gastric cancer 
xenografts in mice. Restoration of DACT2 expression inhibits both canonical and noncanonical WNT signaling in 
SGC7901 cells. Restoration of DACT2 expression sensitized gastric cancer cells to paclitaxel and 5-FU. In conclu-
sion, DACT2 is frequently methylated in human gastric cancer and DACT2 expression is silenced by promoter region 
hypermethylation. DACT2 suppressed gastric cancer proliferation, invasion and metastasis by inhibiting Wnt signal-
ing both in vitro and in vivo.
Keywords: Gastric cancer, DACT2, DNA methylation, Wnt signaling pathway, chemo-sensitivity 
Introduction
Gastric cancer is one of the most common 
malignancies and the second leading cause of 
cancer-related death globally [1, 2]. Both genet-
ics and epigenetics seem to play important 
roles in gastric cancer [3-6]. Disruption of Wnt 
signaling pathway is most likely one of the 
important dysfunctional pathways responsible 
for gastric cancer pathogenesis [7]. Although 
accumulation of β-catenin is a hallmark of Wnt 
signaling activation, and occurs in more than 
50% of these cancers, less than 30% of gastric 
cancers harbor β-catenin mutations [8-10]. APC 
is also rarely mutated in gastric cancer com-
pared to colon cancer [10]. Thus, other compo-
nents of Wnt signaling may play important roles 
in gastric cancer carcinogenesis. 
Dapper was first isolated from Xenopus by 
Cheyettee et al. in a screen for proteins inter-
acting with Dishevelled (Dvl), a key factor in the 
Wnt signaling pathway [11]. Human DACT1 and 
DACT2 were identified by bioinformatics in 
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2003 [12]. DACT1 is located on human chromo-
some 14q22.3 and has been reported fre-
quently to be methylated in HCC. Human DACT3 
is located on chromosome 19q13.32 and is 
regulated by histone modification in colorectal 
cancer [13, 14]. Human DACT2 has been 
mapped to chromosome 6q27, and has been 
reported to have frequent loss of heterozygosi-
ty in human cancers [12, 15-17]. DACT2 was 
also found to be frequently methylated in 
human lung cancer and hepatocellular cancer 
in our previous study [18, 19]. In this study, we 
analyzed the epigenetic changes and the func-
tion of DACT2 in human gastric cancer.
Material and methods
Human tissue samples and cell lines
167 cases of human primary gastric cancer 
sample and 8 cases of normal gastric mucosa 
were collected from Chinese PLA General 
Hospital in Beijing or Ruijin Hospital in Shanghai. 
Snap-frozen fresh tissue samples were collect-
ed by surgery resection. All samples were col-
lected under the guidelines approved by 
Chinese PLA General Hospital’s institutional 
review board and Ruijin Hospital’s institutional 
review board. The patients include 122 cases 
of male and 45 cases of female. The median 
age is 63.1 years old (range 28–89 years). All 
cancer samples were classified by TNM (UICC 
2009) staging, including 64 cases of stage I 
and II, 103 cases of stage III and IV. Follow-up 
data of 72 patients treated with 5-flurouracil 
(5-FU) plus cisplatin after surgical resection is 
available, including 5-years survival data.
7 gastric cancer cell lines (NCI-N87, BGC- 
823, AGS, MNK45, NUGC3, MGC803 and SGC- 
7901) were previously established from prima-
ry gastric cancer, and maintained in 90% RPMI 
1640 or DMEM (Invitrogen, Carlsbad, CA), sup-
plemented with 10% fetal bovine serum. Cells 
were passaged 1:3 once total confluence 
(approximately 1 × 106 cells) was reached on a 
75 cm2 culture flask (NEST Biotech., Jiangsu, 
China).
5-aza-2’-deoxycytidine treatment
Gastric cancer cell lines (NCI-N87, BGC823, 
AGS, MNK45, MGC803 and SGC7901) were 
split to low density (30% confluence) 12 hours 
before treatment. Cells were treated with 5-aza-
2’-deoxycytidine (5-AZA) (Sigma, St. Louis, MO) 
at a concentration of 2 mM. Growth medium, 
conditioned with 5-AZA at 2 µM, was exchanged 
every 24 hours for total 96 hours treatment. At 
the end of treatment course, RNA was extract-
ed from the cells as described below.
RNA isolation and semi-quantitative RT-PCR 
Total RNA was isolated by Trizol reagent (Life 
Technologies, Gaithersburg, MD). Agarose gel 
electrophoresis and spectrophotometric analy-
sis (A260: 280nm ratio) were used to evaluate 
RNA quality and quantity. RNA was stored at 
-80°C prior to use. 5 µg total RNA was used to 
syntheses first strand cDNA with random 6-mer 
primers and Superscript III-reverse transcrip-
tase kit (Invitrogen, Carlsbad, CA). Following 
first strand synthesis, the reaction mixture was 
diluted to 100 μl by using water. Subsequently, 
2.5 µl of diluted cDNA mixture was used for 
PCR amplification in a final 25 µl reaction vol-
ume. PCR amplification was carried out using 
primers: 5’-GGCTGAGACAACAGGACATCG-3’ (F) 
and 5’-GACCGTCGCTCATCTCGTAAAA-3’ (R). The 
primer set for DACT2 was designed to span 
intronic sequences between adjacent exons in 
order to control for genomic DNA contamina-
tion. A total of 33 cycles of amplification were 
performed for each of the RT-PCR experiments. 
As an internal control, GAPDH was amplified 
with 25 cycles to ensure cDNA quality and 
quantity for each RT-PCR. GAPDH primers were 
as follows: 5’-GACCACAGTCCATGCCATCAC-3’ (F) 
and 5’-GTCCACCACCCTGTTGCTGTA-3’ (R). Am- 
plified products were analyzed on 1.5% aga-
rose gels. 
DNA extraction and methylation specific PCR 
(MSP)
Genomic DNA from gastric cancer cell lines, 
167 cases of gastric cancer, and 8 cases of 
normal gastric mucosa were isolated by pro-
teinase K method. Then DNA was dissolved in 
low TE buffer and stored at -20°C. 2 μg genom-
ic DNA was diluted in 50 μl of water. Then 
genomic DNA from primary gastric cancer and 
cell lines was bisulfite modified as previously 
described [20]. MSP primers were designed 
according to genomic sequences flanking pre-
sumed transcription start sites (TSS). Primers 
were synthesized (Invitrogen, Beijing) to detect 
bisulfite-induced changes affecting unmethyl-
ated (U) and methylated (M) alleles. MSP prim-
er sequences are as follows: 5’-GCGCGT- 
GTAGATTTCGTTTTTCGC-3’ (MF); 5’-AACCCCAC- 
GAACGACGCCG-3’ (MR); 5’-TTGGGGTGTGTGTA- 
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GATTTTGTTTTTTGT-3’ (UF) and 5’-CCCAAACC- 
CCACAAACAACACCA-3’ (UR). The size of unme- 
thylated PCR product is 161 bp and methyla-
tion PCR product is 152 bp. Each MSP reaction 
included approximately 100 ng of bisulfite-
treated DNA, 25 pmoles of each primer, 100 
pmoles dNTPs, 2.5 μl 10 × PCR buffer, and 1 
unit of Taq Polymerase (Invitrogen, Carlsbad, 
CA) in a final reaction volume of 25 µl. Cycle 
conditions: 95°C × 5 min, 1 cycle; 35 cycles × 
(95°C × 30 sec, 62°C × 30 sec, 72°C × 40 sec); 
72°C × 5 min, 1 cycle. Each PCR assay includ-
ed a methylation control (in vitro methylated 
DNA, IVD), an unmethylated control (normal 
lymphocyte DNA, NL), and negative control 
(ddH2O). MSP products were analyzed using 2% 
agarose gel electrophoresis.
Immunohistochemistry (IHC)
Immunohistochemistry was performed accord-
ing to previous report [18]. Rabbit anti-DACT2 
antibody was diluted to 1/400 (OriGene Tech., 
MD, U.S.A.). The procedure was performed 
according to catalyzed signal amplification sys-
tem instructions (ZSGB Biotech., Beijing, 
China). 
The expression level of DACT2 was evaluated 
by both intensity and extent of the positive 
staining. The intensity of DACT2 expression 
was quantified using scores as follow: 0 = nega-
tive, 1 = weakly positive, 2 = moderately posi-
tive and 3 = strongly positive. The extent of 
DACT2 expression was quantified as percent-
age of positive staining areas in relation to 
whole tissue areas. The score standard is 
shown as follows: 0 = 0% reactivity, 1 = 1–10% 
reactivity, 2 = 11–50% reactivity, 3 = 51–80% 
reactivity and 4 points means samples is with 
>80% reactivity. The final IHC score was deter-
mined by multiplying intensity score by extent 
score, with the minimum score of 0 and maxi-
mum score of 12 points. So IHC scores are 
including 10–12: strong DACT2 expression 
(+++), 7–9: intermediate DACT2 expression 
(++), 3–6: weak DACT2 expression (+), and 0–2: 
negative DACT2 expression (-). Score of 3 points 
or greater was considered positive for DACT2 
expression. 
Construction of expression vectors
Full-length DACT2 cDNA (GenBank accession 
number NM_214462) was cloned by RT-PCR 
into pCMV6 vector (OriGene Tech., MD, USA).
RNA interference-mediated knockdown of 
DACT2 
DACT2 siRNA were constructed by Gimma com-
pany in Shanghai, as follow: DACT2 8#( the 
complementary sequence with DACT2 mRNA ) 
5’-GUCGGUUGAUGAGACUACUTT-3’ and 5’-AG- 
UAGUCUCAUCAACCGACTT-3’; siRNA con vector 
(the random sequence as control that was not 
related to DACT2 mRNA) 5’-UUCUCCGAAC- 
GUGUCACGUTT-3’ and 5’-ACGUGACACGUUCG- 
GAGAATT-3.
Transfection assay
Transient transfection was performed by using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
or FuGENE 6 (Roche Applied Science, In- 
dianapolis, IN) according to manufacturer’s 
instructions.
Colony formation assay 
SGC7901 cells were seeded in 6-well culture 
plates 24 h before transfection. DACT2 expres-
sion or empty vector was transfected into 
SGC7901 cells. Cells were digested and 
reseeded at 1500 cells/ well in 6-well plates in 
triplicate after 36 h. Growth medium, condi-
tioned with G418 (Invitrogen, Carlsbad, CA) at 
400 µg/mL, was exchanged every 24 h. Clones 
were counted by 14 days after fixed with 75% 
ethanol for 30 min and stained with 0.2% crys-
tal violet for visualization and counting. 
Flow cytometry assay
The Cell phase was determined by quantitation 
of cellular DNA content with propidium iodide 
(PI) staining (KeyGen Biotech., Jiangsu, China). 
DACT2 expression or empty vectors were trans-
fected into SGC7901 cells according to manu-
factory’s instruction (KeyGEN Biotech, Nanjing, 
China). After 48 h of transfection, cells were 
collected and then sorted by FACS Calibur (BD 
Biosciences, Franklin Lakes, NJ). Cell-cycle pro-
files were analyzed by WinMDI v. 2.9 software 
(Scripps Research Institute, La Jolla, CA).
Chemo-sensitivity assay
The cytotoxic effects of paclitaxel, cisplatin and 
5-fluorouracil (5-FU) on SGC7901 cells were 
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determined using Cell Counting Kit-8 (CCK-8). 
Briefly, cells were seeded at 4,000/well onto 
flat-bottomed 96-well culture plates and 
allowed to grow for 48 hours before the desired 
treatment. Cells were then detected with CCK-8 
(Dojindo, Japan) according to the manufactur-
er’s instruction. Absorbance was read in a 
microplate reader at 450 nm. The half maximal 
inhibitory concentration (IC50) value was 
assessed by different concentrations of pacli-
taxel (0, 0.001, 0.01, 0.05, 0.1, 1 μM), cisplatin 
(0, 1, 2, 5, 10, 20 μM) and 5-FU (0, 1, 10, 100, 
500, 1000 μM).
Cell invasion assay 
The effect of DACT2 on cell invasion was detect-
ed by the Transwell assay (COSTAR transwell, 
Corning Incorporated, MA, USA). SGC7901 cells 
were transfected with empty vector or DACT2 
vector. 3 × 105 cells were suspended in 500 µl 
of serum-free DMEM and loaded onto the upper 
compartment of an invasion chamber contain-
ing a polycarbonate membrane with an 8 µm 
pore size which was coated with a layer of 
extracellular matrix (ECM; Matrigel™, BD, NJ, 
USA). After 12 h of incubation, the invasive 
cells migrated through the ECM layer to the 
complete medium in the lower compartment. 
The invasive cells were stained with crystal vio-
let and the number of invaded cells was count-
ed in three independent high powered fields (× 
100) readings with a light microscope. 
Statistical analysis was applied among the 
groups.
Transwell migration assay
The effect of DACT2 on cell migration was 
detected by using the Transwell assay in the 
absence of the ECM layer. SGC7901 cells were 
transfected with empty vector or DACT2 expres-
sion vector. After 48 h, DACT2 forced expres-
sion cells, empty vector transfected cells, or 
untransfected cells were harvested and sus-
pended in the serum free DMEM. Cell suspen-
sions were then placed into the upper well at a 
concentration of 1 × 104 cells/100 µl separate-
ly, while the complete medium with 10% fetal 
bovine serum was placed into the lower well 
(500 µl). The chamber was incubated for 6h. 
Non-migrated cells on the upper surface were 
scraped gently and washed out with PBS three 
times. DACT2 cells migrated to the lower sur-
face of the membrane were stained with crystal 
violet and counted in three independent high 
powered fields (× 100) with light microscope. 
Statistical analysis was applied among groups.
DACT2 silenced and re-expressed SGC7901 
cells xenograft mice 
DACT2 re-expressed SGC7901 stable cell line 
(2 × 106 cells in 0.2 ml phosphate-buffered 
saline) was injected subcutaneously into the 
dorsal right flank of 4-week-old female Balb/c 
nude mice (n = 6), and DACT2 unexpressed 
SGC7901 cell line was injected subcutaneously 
into the dorsal left flank of the same nude mice 
(n = 6). 5 days after implantation, tumor volume 
was assessed every 2 days for 3 weeks. Tumor 
volume was calculated according to the follow-
ing formula: V = L × W2/2 where V, volume 
(mm3); L, biggest diameter (mm); W, smallest 
diameter (mm). All procedures were approved 
by the Animal Ethics Committee of the Chinese 
PLA General Hospital.
Luciferase reporter assay 
Cells were seeded at 5 × 104 cells/well in 
24-well culture plates 24 h before transfection. 
pGL3-OT construct is a TCF/LEF–responsive 
reporter containing three consensus TCF bind-
ing sites. pRL-TK vector (Promega, Madison, WI) 
was used as a system control [18, 19, 21, 22]. 
100 ng/well pGL3-OT and 10 ng/well pRL-TK 
vector were transfected into SGC7901 cell line 
as basic luciferase reporter system [21]. 150 
ng/well wild type or Ser45 mutation β-catenin 
vector was transfected into SGC7901 cell line 
as wild type or mutant β-catenin expression 
groups [23]. To explore the effect of DACT2 on 
β-catenin/TCF luciferase reporter activity, 
100ng/well DACT2 vectors was transfected 
into wild type and mutant β-catenin expression 
SGC7901 cells. 
Relative luciferase activity was measured by 
the Dual Luciferase Reporter Assay system 
(Promega) according to the manufacturer’s 
instruction 48 h after transfection. Each experi-
ment was repeated for three times.
Western blot 
To further validate the effect of DACT2 on Wnt 
signaling pathway, DACT2 expression construct 
or empty vector was transfected into SGC7901 
cells. Cells were harvested and lysed in ice-cold 
Tris buffer (20 mmol/L Tris; pH 7.5) containing 
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137 mmol/L of NaCl, 2 mmol/L of EDTA, 1% 
Triton X, 10% glycerol, 50 mmol/L of NaF, 1 
mmol/L of DTT, and a protease inhibitor cock-
tail (Roche Applied Science) after 48 hours of 
transfection. 45 µg of cell lysate was loaded 
into each lane. The protein lysates were then 
separated by SDS-PAGE and electroblotted 
onto PVDF membranes (Hybond-P, Amersham). 
After blocking with 5% nonfat milk and 0.1% 
Tween-20 in TBS, the membranes were incu-
bated with rabbit anti-DACT2 (Abcam, MA, 
USA), rabbit anti-cyclinB1 (Bioworld Tech., MN, 
USA), rabbit anti-cdc2 (Bioworld Tech., MN, 
USA), rabbit anti-c-Myc (Bioworld Tech., MN, 
USA), rabbit anti-MMP-2 (Bioworld Tech., MN, 
USA), rabbit anti-MMP-9 (Bioworld Tech., MN, 
USA), rabbit anti-p-c-Jun (Epitomics, USA), rab-
bit anti-β-catenin (Epitomics, USA), p-β-ca- 
tenin (CST, USA) or mouse anti-β-actin (Beyo- 
time Biotech., China) antibodies. The blots were 
visualized using enhanced chemiluminescence 
(Pierce Bioscience, IL, USA). 
Statistical analysis
Data were presented as mean ± SD. Statistical 
analysis was carried out by X2 test and t test. 
Figure 1. Dact2 is silenced by promoter region hypermethylation in gastric cancer. A. RT-PCR results of DACT2 ex-
pression: (-) untreated; (+) 5-AZA treated. H2O: double distilled water. GAPDH: internal control. B. Methylation status 
of DACT2 in gastric cancer cell lines. C. Representative MSP results: GC: gastric cancer; IVD: in vitro methylated 
DNA; NL: normal lymphocyte DNA; U: unmethylated alleles; M: methylated alleles. D. NG: normal gastric mucosa. E. 
IHC staining of DACT2 in gastric cancer and adjacent tissue (×400). DACT2 expression is associated with promoter 
region hypermethylation in reversely (X2 test, P = 0.049).
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Table 1. The association of clinic-pathologic characteristics and methylation status of DACT2 in gas-
tric cancer patients (n = 167)
Clinical parameter No.
Methylation status
P valuea
Methylated n = 93 (55.7%) Unmethylated n = 74 (44.3%)
Age (year) P = 0.4886
    <50 30 15 (50%) 15 (50%)
    ≥50 137 78 (56.9%) 59 (43.1%)
Gender P = 0.4958
    Male 122 66 (54.1%) 56 (45.9%)
    Female 45 27 (60%) 18 (40%)
Differentiation P = 0.0185*
    Poorly 113 70 (61.9%) 43 (38.1%)
    Moderately/Well 48 23 (47.9%) 31 (52.1%)
Tumor stage P = 0.4497
    I/II 64 38 (59.3%) 26 (40.7%)
    III/IV 103 55 (53.4%) 48 (46.6%)
T stage P = 0.0461*
    1/2 29 21 (72.4%) 8 (22.6%)
    3/4 138 72 (52.2%) 66 (47.8%)
N stage P = 0.8822
    Negative 37 21 (56.8%) 16 (43.2%)
    Positive 130 72 (55.4%) 58 (44.6%)
Intravascular cancerous emboli P = 0.0347*
    Negative 83 53 (63.9%) 30 (36.1%)
    Positive 84 40 (47.6%) 44 (52.4%)
Tumor size P = 0.2187
    ≥5 cm 110 65 (59.1%) 45 (40.9 %)
    <5 cm 57 28 (49.1%) 29 (50.9%)
aP values are obtained from X2 test; *Statistically significant, P < 0.05. 
Kaplan-Meier was performed for survival cur- 
ves. P<0.05 was considered significant diffe- 
rence.
Results
DACT2 expression was regulated by promoter 
region hypermethylation in gastric cancer
To explore the possibility of epigenetic regula-
tion of DACT2 in human gastric cancer, 7 
human gastric cancer cell lines were detected 
by semi-quantitative RT-PCR. DACT2 expres-
sion was discovered in NCI-N87, BGC823, AGS, 
MNK45, NUGC3 and MGC803 cell lines and no 
expression was found in SGC7901 cell line 
(Figure 1A). DACT2 was found completely meth-
ylated in SGC7901 cell line and partially meth-
ylated inBGC823 cell line, the other cells were 
unmethylated (Figure 1B). The results indicate 
that loss of DACT2 expression is correlated 
with promoter region hypermethylation in 
human gastric cancer cells. Induced expres-
sion of DACT2 by 5-AZA, a DNA methylation 
transferases (DNMTs) inhibitor, was revealed in 
SGC7901 cell line. But no expression change 
was found in the other cells before and after 
5-AZA treatment. Above results indicate that 
DACT2 expression was regulated by promoter 
region methylation in human gastric cancer. 
DACT2 is frequently methylated in human 
gastric cancer and methylation of Dact2 is as-
sociated with reduction of DACT2 expression in 
primary cancer samples
DACT2 was methylated in 55.7% (93/167) of 
primary gastric cancer (Figure 1C) and no meth-
ylation was found in 8 cases of normal human 
gastric mucosa (0/8) (Figure 1D). DACT2 meth-
ylation is associated with tumor differentiation 
(P<0.05), invasion (P<0.05), and intravascular 
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cancerous emboli significantly (P<0.05, Table 
1).
To evaluate the expression of DACT2 in primary 
gastric cancer, 42 cases of available paired 
gastric cancer and adjacent tissue sample 
were stained by IHC. DACT2 staining was main-
ly located in cytoplasm. Positive staining was 
found in 14 cases of gastric cancer and 32 
cases of adjacent tissue (Figure 1E). The 
expression level is reduced significantly in can-
cer tissue (P<0.01). In 42 cases of cancer tis-
sue samples, 21 cases were methylated 
(including 17 negative staining cases and 4 
positive staining cases) and 21 cases (includ-
ing 11 negative staining cases and 10 positive 
staining cases) were unmethylated. DACT2 
expression is associated with promoter region 
Figure 2. Colony formation, migration and inva-
sion were inhibited by restoration of DACT2 ex-
pression in SGC7901 cells. And the migration 
and invasion were promoted by knock down of 
DACT2 in AGS cells. A. Colony formation results: 
the average number of colonies is presented in 
bar diagram. B. Restoration of DACT2 expression 
inhibits the migration and invasion in SGC7901 
cells. C. Western Blot results: MMP-9, and MMP-
2 expression were inhibited by restoration of 
DACT2 expression in SGC7901 cells and were 
increased by knock down of DACT2 expression 
in AGS cells.
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Figure 3. Cell phase distribution and G2/M phase related protein 
expression before and after re-expression DACT2 (A) Restoration 
of DACT2 expression reduced S phase and increased G2/M phase 
cells. (B) The ratio of each phase is presented by bar diagram. (C) 
The expression of cdc2 and cyclinB1 in DACT2 unexpressed and 
expressed SGC7901 cells or before and after siRNA knock down 
DACT2 in AGS cells.
DACT2 is a Wnt signaling inhibitor in gastric cancer
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hypermethylation in reversely (X2 test, P<0.05). 
Above results hint that DACT2 expression is 
regulated by promoter region hypermethylation 
in primary gastric cancer. 
Restoration of DACT2 expression inhibits 
colony formation, migration and invasion of 
SGC7901 cells
To evaluate the effect of DACT2 on cell prolifer-
ation in gastric cancer, a colony formation 
assay was employed in SGC7901 cell line. As 
shown in Figure 2A, the clone number was 
reduced significantly in DACT2 re-expressed 
SGC7901 cells compared with control group 
(54.67±14.0 vs 113.67±22.5, P<0.05). The 
result suggests that DACT2 inhibits cell prolif-
eration in gastric cancer.
To evaluate the effect of DACT2 on gastric can-
cer migration and invasion, the Transwell assay 
was employed. In the Transwell assay without 
ECM coating, the number of migrated cells in 
each high powered field was 189 ± 36 in the 
DACT2 re-expressed SGC7901 cells, and 
327±33 in the empty vector group under the 
microscope (Figure 2B). The number of migrat-
ed cells is reduced significantly in DACT2 re-
expressed SGC7901 cells compared to the 
empty vector group (P<0.05). The invasive cell 
number of each high powered field was 96±9 in 
the DACT2 expression group and 202±43 in 
the empty vector group (Figure 2B). The num-
ber of invasive cells was significantly reduced in 
the DACT2 re-expressed SGC7901 cells com-
pared with the control group (P<0.05). These 
results indicate that DACT2 suppresses cellular 
invasion and migration in gastric cancer. The 
expression of MMP-2 and MMP-9, the major 
components related to cancer invasion and 
migration, was inhibited after re-expression of 
DACT2 in SGC7901 cells. This effect was fur-
ther validated by knock down of DACT2 in 
DACT2 expressed AGS cells (Figure 2C). Above 
results suggest that DACT2 inhibits cell inva-
sion and migration in gastric cancer. 
Re-expression of DACT2 induced G2/M phase 
arrest in gastric cancer cells 
The effect of DACT2 on the cell cycle was evalu-
ated by flow cytometry. In SGC7901 cells trans-
fected with an empty vector, the percentage of 
G0/1 phase was 44.1±5.95%, S phase was 
44.1±5.95 and G2/M phase was 6.63±3.37%. 
In contrast, in DACT2 re-expressed SGC7901 
cells, the ratio of G0/1 phase was 43.92±3.01%, 
S phase was 34.13±2.21% and G2/M phase 
was 21.96±5.21% (Figure 3A). The ratio of S 
phase was reduced significantly (34.13±2.21% 
vs. 44.1±5.95%, P<0.01), and the ratio of 
G2/M phase was increased significantly after 
restoration of DACT2 expression (21.96±5.21% 
vs 6.63±3.37%, P<0.01, Figure 3B). These 
results indicate that DACT2 reduced S phase 
and induced G2/M phase arrest in SGC7901 
cells. 
To further validate the effect of DACT2 on G2/M 
phase, cdc2 and cyclinB1 (G2/M check point 
Figure 4. DACT2 inhibits both Wnt/β-catenin and Wnt/c-Jun signaling pathway. A. Results of TCF/LEF luciferase 
reporter assay. TopFlash: TCF/LEF-responsive reporter; pRL-TK: internal control; WT: wild-type; Mut: mutant. B. p-β-
catenin, β-catenin, C-myc and p-c-Jun expression. p-β-catenin: phosphorylated β-catenin; p-c-Jun: phosphorylated 
c-Jun. Con siRNA: siRNA control; 8# siRNA: DACT2 siRNA #8.
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proteins) were analyzed in DACT2 unexpressed 
SGC7901 cells and DACT2 expressed AGS 
cells. As shown in Figure 3C, the expression of 
cdc2 and cyclinB1 was suppressed after resto-
ration of DACT2 expression in SGC7901 cells 
and their expression was enhanced when a 
knock down of DACT2 in AGS cells occurred. 
These results further validate that DACT2 may 
induce G2/M arrest in gastric cancer.  
DACT2 inhibits both canonical Wnt/β-catenin 
signaling and noncanonical Wnt/c-Jun signal-
ing in gastric cancer
As shown in Figure 4A, the activity of TCF/LEF 
luciferase reporter was inhibited by co-trans-
fecting DACT2 with wild type or mutant type of 
β-catenin in SGC7901 cells. The expression 
ofβ-catenin and c-myc, the Wnt signaling down-
Figure 5. DACT2 suppressed SGC7901 cell xenograft growth. A and B. DACT2 unexpressed and expressed SGC7901 
cell xenograft. C. Tumor growth curve in DACT2 vector and Empty vector groups. D and E. Diagrams show the volume 
and weight in DACT2 expressed and unexpressed SGC7901 cell xenografts.
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the volume of gastric cancer is significantly dif-
ferent in DACT2 re-expressed and unexpressed 
SGC7901 xenograft mice (14.33±7.05 mm3 vs. 
307.46±140.42 mm3, t test, P<0.05). The 
weight of the tumor is also significantly differ-
ent in DACT2 re-expressed and unexpressed 
SGC7901 xenograft mice (25.05±2.0 mg vs 
365.67±20.02 mg, t test, P<0.01) (Figure 5C). 
DACT2 expression was validated by IHC in 
stream genes, were reduced and the level of 
p-β-catenin (phosphorylated β-catenin) was 
increased in DACT2 re-expressed SGC7901 
cells. The effect of DACT2 on Wnt/β-catenin 
signaling was further validated by knocking 
down DACT2 in DACT2 constant expressed AGS 
cells. The level of p-β-catenin was reduced and 
the expression ofβ-catenin and c-myc were 
increased by knocking down DACT2 in AGS 
cells (Figure 4B). These res- 
ults suggest that DACT2 inhi- 
bits Wnt/β-catenin signaling 
in gastric cancer. 
Since DACT2 inhibits TCF/LEF 
activity under overexpression 
of both wild type and mutant 
type β-catenin in SGC7901 
cells, it is possible that DACT2 
may be involved in both the 
canonical Wnt/β-catenin and 
the noncanonical Wnt/c-Jun 
pathway [11]. To validate if 
DACT2 involved the nonca-
nonical Wnt/c-Jun signaling, 
c-Jun was detected by west-
ern blot in DACT2 unex-
pressed and re-expressed 
SGC7901 cells as well as in 
AGS cells before and after 
knock down of DACT2. As 
shown in Figure 4B, the 
expression of c-Jun was dec- 
reased after restoration of 
DACT2 expression in SGC- 
7901 cells and increased by 
knocking down DACT2 in AGS 
cells. These results suggest 
that DACT2 is involved in the 
noncanonical Wnt/c-Jun sign- 
aling.
DACT2 suppressed gastric 
cancer growth in xenograft 
mice 
To further understand the 
effect of DACT2 on gastric 
cancer, DACT2 re-expressed 
and unexpressed SGC7901 
xenograft mice were emplo- 
yed in this study (Figure 5A). 
As shown in Figure 5B, 5C, 
Figure 6. The predictive value of DACT2 methylation in chemo-sensitivity. A. 
The five-year survival rates in Dact2 methylated and unmethylated patients. 
B. The sensitivity of SGC7901 cells to 5-FU and cisplatin before and after 
re-expression of DACT2. The cell viability was measured by CCK-8 after treat-
ment with different concentration of cisplatin for 48h. C. The sensitivity of 
DACT2 unexpression and expressed SGC7901 cell to paclitaxel.
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DACT2 expressed SGC7901 xenografts (Figure 
5D). These results suggest that DACT2 sup-
presses SGC7901 xenograft growth in mice.
DACT2 methylation is related to 5-FU and 
cisplatin sensitivity in human primary gastric 
cancer, and DACT2 sensitizes SGC7901 cells 
to paclitaxel 
In 72 cases of gastric cancer patients with 
available follow-up data, the five-year survival 
rates were 53% in DACT2 methylated and 33% 
in unmethylated patients, which was treated by 
5-FU plus cisplatin after surgical resection 
(Figure 6A). It suggests that DACT2 methylation 
may be a sensitive marker for 5-FU and/or cis-
platin in gastric cancer. Further analysis was 
performed to investigate the sensitivity of 5-FU 
or cisplatin in gastric cancer cells. As shown in 
Figure 6B, the IC50 of 5-FU are 62.75±4.47 μM 
and 48.18±3.23 μM in DACT2 unexpressed 
and re-expressed SGC7901 cells, resectively 
(P<0.05). The IC50 of cisplatin are 12.75 ± 
1.01 μM and 16.78 ± 0.65 μM in DACT2 unex-
pressed and re-expressed SGC7901 cells. 
DACT2 unexpressed SGC7901 cell is more sen-
sitive than DACT2 expressed SGC7901cell to 
cisplatin (P<0.01).
Paclitaxel exerts its cytotoxic activity through 
enhancement and stabilization of the microtu-
bule assembly reducing their dynamicity lead-
ing to an arrest of the cell cycle at the G2/M 
phase. As G2/M arrest was induced by DACT2 
in SGC7901 cells, the sensitivity of paclitaxel in 
SGC7901 cells was detected before and after 
restoration of DACT2 expression (Figure 6C). 
The IC50 of paclitaxel is lower in DACT2 re-
expressed SGC7901 cells than in control group 
after 48 hours treatment (0.064±0.0076 μM vs 
0.10±0.016 μM, P< 0.01). Above results indi-
cate that DACT2 sensitized SGC7901 cells to 
paclitaxel. Paclitaxel and 5-FU are more sensi-
tive to DACT2 expressed SGC7901 cells than 
DACT2 unexpressed SGC7901 cells, but cispla-
tin is more sensitive to DACT2 unexpressed 
SGC7901 cells than expressed DACT2 SGC- 
7901 cells.
Discussion
In this study, we found DACT2 expression was 
absent or reduced in human gastric cancer. 
This result is similar to our previous reports 
regarding DACT2 expression in human lung 
cancer and hepatic cancer [18, 19]. DACT2 is 
located on human chromosome 6q27 [12]. This 
region is frequently lost in various human can-
cers, including gastric cancer [15-17]. Chen et 
al reported that LOH on chromosome 6q exists 
in 80% of Chinese gastric cancer, suggesting 
the presence of tumor suppressor genes in 6q 
[24]. As reported previously, DACT2 expression 
is mainly regulated by promoter region hyper-
methylation and not by mutation in human lung 
cancer [18, 19]. In this study, we also found 
that DACT2 was frequently methylated in 
human gastric cancer and its expression was 
silenced by promoter region hypermethylation. 
It suggests that methylation of DACT2 is a 
potential gastric cancer detection biomarker. 
DACT2 methylation was also significantly asso-
ciated with tumor differentiation (P<0.05), inva-
sion (P<0.05) and intravascular cancerous 
emboli (P<0.05). These findings indicate that 
methylation of DACT2 promotes gastric cancer 
development and invasion. To analyze the 
effect of DACT2 on gastric carcinogenesis fur-
ther, colony formation assay, flow cytometry 
and a Transwell assay were all employed. 
Restoration of DACT2 expression inhibited col-
ony formation, induced G2/M arrest, and inhib-
ited cell migration and invasion in a SGC7901 
cell line. Tumor growth was also inhibited by 
DACT2 expression in mice xenografted with 
SGC7901 cells. All of the above results suggest 
that DACT2 is a tumor suppressor in human 
gastric cancer.
In the canonical Wnt/β-catenin pathway, re- 
duced degradation of β-catenin will increase 
translocation of β-catenin into the nucleus, and 
activate TCF/LEF and downstream targets [25-
28]. C-myc and MMPs are downstream targets 
of Wnt/β-catenin signaling. In our study, re-
expression of DACT2 inhibited TCF/LEF activity, 
and the effect was tempered by co-transfection 
of β-catenin with DACT2 in SGC7901 cells. The 
downstream targets, c-myc and MMPs, were 
reduced. Phosphorylated β-catenin was, how-
ever, increased. These results suggest that 
DACT2 is involved in the canonical Wnt/ 
β-catenin pathway in gastric cancer. Dpr2 pro-
teins are conserved from zebrafish to human in 
four conserved domains: an NH2-terminal leu-
cine-zipper domain, two serine-rich domains, 
and a binding motif for PDZ domain at the 
C-terminus [11, 12, 27, 29-31]. Only the PDZ-
binding motif was identified to bind Dishevelled 
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whereas the function of the other domains 
remains unclear [11]. Cheyette et al. reported 
that Dpr inhibits noncanonical Wnt/c-Jun sig-
naling in Xenopus [11]. Su et al. found that 
mouse DACT2 antagonize TGF-βsignaling [32].
Our previous study demonstrated that DACT2 
inhibits Wnt signaling in human lung and hepat-
ic cancer [27, 33]. This study indicates that 
DACT2 inhibits noncanonical Wnt/c-Jun signal-
ing in human gastric cancer. These results sug-
gest that the function of DACT2 may be partially 
different in different species or different tis-
sues. The ratio of G2/M phase is increased 
after restoration of DACT2 expression in 
SGC7901 cells. As reported before, G2/M 
phase cells is sensitive to paclitaxel [34]. Our 
results indicate that DACT2 re-expressed 
SGC7901 cells are more sensitive to paclitaxel, 
but DACT2 unexpressed SGC7901 cells are 
more sensitive to cisplatin. While, in primary 
gastric cancer patients treated by 5-FU plus 
cisplatin, the five-year survival rates were high-
er in Dact2 methylated than in unmethylated 
patients. The IC50 of 5-FU is very high in both 
DACT2 unexpressed and re-expressed SGC- 
7901 cells, The IC50 of cisplatin and paclitaxel 
is very low in DACT2 unexpressed and re-
expressed SGC7901 cells. Cisplatin may play a 
more important role than 5-FU in combined 
5-FU and cisplatin therapy in gastric cancer. 
Our results suggest that DACT2 methylation is 
a sensitive marker of cisplatin and a marker of 
insensitivity for paclitaxel. DACT2 methylation 
is associated with tumor differentiation 
(P<0.05), invasion (P<0.05) and intravascular 
cancerous emboli (P<0.05). These results sug-
gest that DACT2 may involve gastric cancer 
development and progression. Functional stud-
ies further validated that DACT2 inhibited colo-
ny formation, cell migration and invasion in gas-
tric cancer cells. In vivo, DACT2 seemed to 
suppress gastric cancer xenograft. All of these 
above results suggest that DACT2 is a tumor 
suppressor in human gastric cancer. Our results 
further reveal that DACT2 suppresses gastric 
cancer growth through both the canonical Wnt/
β-catenin pathway and the noncanonical Wnt/
c-Jun Signaling.
In conclusion, DACT2 is frequently methylated 
in human gastric cancer and DACT2 expression 
was silenced by promoter region hypermethyl-
ation. Methylation of DACT2 promotes gastric 
cancer growth, invasion and metastasis both in 
vitro and in vivo. Methylation of DACT2 activat-
ed both the canonical Wnt/β-catenin signaling 
and noncanonical Wnt/c-Jun signaling in gas-
tric cancer. In 5-FU plus cisplatin treated gas-
tric cancer patients, the five-year survival rates 
was higher in DACT2 methylated patients. 
Restoration of DACT2 expression sensitized 
paclitaxel and 5-FU to gastric cancer cells.
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